GENFIT S.A.: GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate ...
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibran ...
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...
CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of ...
CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy ...
Forbes9 天
The Recent Surge in Drug Costs and What Can Be Done About It
Used to treat urea cycle disorders (UCDs), a genetic condition that can cause ammonia to build up in the body. Ravicti is an ...
Healthshots on MSN3 天
6 reasons behind your dry, itchy skin – and how to prevent it
Do you often find yourself constantly scratching your skin because it feels dry and uncomfortable? Dry, itchy skin is a ...
eLife9 天
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose ...
The authors present a valuable study exploring the interaction between JNK signaling and high sucrose feeding. The strength of evidence supporting these observations is solid, including multi-tissue ...